-
May 15, 2013
The firm which holds the patent on two genes that increase risk of a certain breast cancer is currently embroiled in a Supreme Court case in the USA
Full story
-
May 03, 2013
But new drugs and greater awareness means that fewer women are dying from the disease
Full story
-
April 30, 2013
Hundreds of women with breast cancer who live in the most deprived areas of England would have better survival rates if they were diagnosed at the same stage as those who live in affluent areas, new research has revealed.
Full story
-
April 16, 2013
The US Supreme Court has begun to hear arguments in a keenly-watched gene patent case involving Myriad Genetics which observers believe could shape the whole future of medical research
Full story
-
April 11, 2013
Shares in Pfizer have climbed after regulators in the USA agreed to fast-track its new breast cancer drug palbociclib
Full story
-
April 10, 2013
Expanding its Asia focus, GlaxoSmithKline has signed up Hong Kong-based Eddingpharm to sell its breast cancer drug Tykerb in China, having just entered into an alliance with Singapore's A*Star to develop medicines for emerging market
Full story
-
March 06, 2013
As expected, regulators in Europe have given the green light to Roche's Perjeta as a treatment for breast cancer
Full story
-
February 28, 2013
The market for breast cancer drug therapies in Brazil, Russia, India and China (the BRIC nations) will grow by an annual average rate of 8% over the next five years, increasing from $1.7 billion in 2012 to $2.5 billion in 2017, according to new forecasts.
Full story
-
February 25, 2013
The US Food and Drug Administration has approved Roche's much-touted antibody drug conjugate Kadcyla for patients with HER2-positive, late-stage breast cancer
Full story
-
February 19, 2013
New draft guidance from NICE recommends that the NHS should use one test, Oncotype DX, to guide decisions about the use of chemotherapy in people with early breast cancer, but not three others.
Full story